API
< Back to all clusters
[BUSINESS] · South Korea, Mexico · 2 sources

started · updated

Peptron receives Mexican approval for long-acting prostate cancer treatment

Peptron has obtained marketing authorization from Mexico’s Federal Commission for Protection against Sanitary Risk (COFEPRIS) for its long-acting prostate cancer and precocious puberty treatment, Lupunia (PT105).

Lupunia is a monthly injectable containing leuprorelin and represents the first commercialized product to utilize Peptron’s proprietary SmartDepot drug delivery platform. The company has demonstrated bioequivalence with the original Japanese product and has secured pharmacokinetic equivalence based on advanced country standards for the first time outside of Japan.

The approval was facilitated by a regulatory shift in which COFEPRIS recognized South Korea’s Ministry of Food and Drug Safety as a reference regulatory authority, allowing for an abbreviated regulatory pathway. Peptron intends to use Mexico as a strategic hub to expand its presence into the Latin American market, where the market for leuprorelin-based anticancer drugs has grown significantly.

Entities

Cofepris · Mexico · Peptron · South Korea